Major phase 2 and 3 studies of autologous SCT in MCL
| Trial . | Phase . | Number of patients . | ORR/CR . | PFS/OS . | Reference . |
|---|---|---|---|---|---|
| Consolidation by myeloablative radiochemotherapy followed by ASCT vs interferon maintenance | 3 | 269 | 3.3 vs 1.5 years/7.5 vs 4.8 years | 3 | |
| R-CHOP/R-DHAP+ASCT vs R-CHOP+ASCT (MCL Younger) | 3 | 497 | 8.4 years vs 3.9 years/NR vs 11.3 years | 2 | |
| R-maxi-CHOP/HIDAC (Nordic MCL2) followed by ASCT | 2 | 160 | 8.5 years/12.7 years | 4 | |
| R-DHAP+ASCT followed by MR vs R-DHAP+ASCT followed by consolidation | 3 | 299 | 89%/77% | 4 year PFS 83% vs 64%/4-year OS 89% vs 80% | 11 |
| R-CHOP/R-DHAP+ASCT vs R-CHOP-I/R-DHAP+ASCT followed by I maintenance vs R-CHOP-I/R-DHAP followed by I maintenance (TRIANGLE) | 3 | 860 | 98% (A + I and I combined) vs 94% (A)/45% (A + I and I combined) vs 36% (A) | 3-year FFS 72% vs 88% vs 86%/3-year OS 86% vs 91% vs 92% | 14 |
| Trial . | Phase . | Number of patients . | ORR/CR . | PFS/OS . | Reference . |
|---|---|---|---|---|---|
| Consolidation by myeloablative radiochemotherapy followed by ASCT vs interferon maintenance | 3 | 269 | 3.3 vs 1.5 years/7.5 vs 4.8 years | 3 | |
| R-CHOP/R-DHAP+ASCT vs R-CHOP+ASCT (MCL Younger) | 3 | 497 | 8.4 years vs 3.9 years/NR vs 11.3 years | 2 | |
| R-maxi-CHOP/HIDAC (Nordic MCL2) followed by ASCT | 2 | 160 | 8.5 years/12.7 years | 4 | |
| R-DHAP+ASCT followed by MR vs R-DHAP+ASCT followed by consolidation | 3 | 299 | 89%/77% | 4 year PFS 83% vs 64%/4-year OS 89% vs 80% | 11 |
| R-CHOP/R-DHAP+ASCT vs R-CHOP-I/R-DHAP+ASCT followed by I maintenance vs R-CHOP-I/R-DHAP followed by I maintenance (TRIANGLE) | 3 | 860 | 98% (A + I and I combined) vs 94% (A)/45% (A + I and I combined) vs 36% (A) | 3-year FFS 72% vs 88% vs 86%/3-year OS 86% vs 91% vs 92% | 14 |
ASCT, autologous stem cell transplantation; CHOP, cyclophosphamid, doxorubicin, vincristine, prednisone; DHAP, dexamethasone, high-dose cytarabine, cisplatin; FFS, failure-free survival; HIDAC, high-dose cytarabine; I, ibrutinib; NR, not reported; OS, overall survival; PFS, progression free survival; R, rituximab.